

Wockhardt Ltd. Pharmaceutical and Healthcare Pipeline Review H2

Wockhardt Ltd. Treatment Pipeline Review H2 2016

PUNE, INDIA, February 28, 2017
/EINPresswire.com/ -- *Get Flat 15% discount*

Summary

This report provides comprehensive information on the current therapeutic developmental pipeline of [Wockhardt Limited's](#), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com
☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <https://twitter.com/WiseGuyReports>
📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/306790-wockhardt-limited-product-pipeline-review-2015>

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

- The report provides brief overview of Wockhardt Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Wockhardt Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Wockhardt Limited's pipeline products

Reasons to buy

- Evaluate Wockhardt Limited's strategic position with total access to detailed information on its product pipeline
 - Assess the growth potential of Wockhardt Limited in its therapy areas of focus
 - Identify new drug targets and therapeutic classes in the Wockhardt Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 - Develop strategic initiatives by understanding the focus areas of Wockhardt Limited and exploit collaboration and partnership opportunities
 - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Wockhardt Limited
 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 - Explore the dormant and discontinued projects of Wockhardt Limited and identify potential opportunities in those areas
 - Avoid Intellectual Property Rights related issues
- ...Continued

Access Report @ <https://www.wiseguyreports.com/reports/306790-wockhardt-limited-product-pipeline-review-2015>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.